汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
Arcellx’s BCMA CAR-T challenges Legend’s Carvykti in multiple myeloma;
Eli Lilly's Imlunestrant, an oral SERD, significantly improved PFS in ER+, HER2- advanced breast cancer patients;
Merck/VelosBio’s ROR1-directed ADC on top of R-CHP showed 100% ORR in 1L DLBCL, with safety signals to inform Phase 3 study of the low dose;
BMS’ TYK2 inhibitor Sotyktu succeeds in two phase 3 trials of psoriatic arthritis;
Merus’ petosemtamab showed standard-of-care potential in 2L+ HNSCC while its zenocutuzumab received FDA accelerated approval to treat NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma;
Janux Therapeutics’ JANX007 showed promising interim phase 1a data in patients with advanced prostate cancer;
Novo Nordisk’s CagriSema showed 22.7% weight loss in a phase 3 obesity trial, falling short of high expectations；
AbbVie announced positive topline results for the third phase 3 trial of Tavapadon in Parkinson’s Disease；
Novartis pays $1B upfront for PTC518, a phase 2 oral drug for Huntington’s Disease;
BMS pays $100M upfront to collaborate with BioArctic on Alzheimer’s drugs.
活动详情
主题：Monthly biotech news discussion - December 2024 in review
时间：2025年1月4日 Sat 8:00 PM（EST）/ 2025年1月5日 周日 早上9:00 AM（北京时间）
地点：药时代视频号
嘉宾：
Jimmy Wang (王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
Ethan Xu (徐亦迅),VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Stephen Yan (严顺飞),BD Search & Evaluation @ AstraZeneca
(https://www.linkedin.com/in/shunfei-yan/)
Xianbo Zhou (周显波), Founder & CEO @ AstraNeura
(https://www.linkedin.com/in/xianbo-zhou-7b33b76/)
Avery Yan (晏庆红), Founder & CEO @ Riboway Therapeutics
(https://www.linkedin.com/in/avery-yan/)
Lihua Yu (于利华), Chief Data Officer @ Fogpharma
(https://www.linkedin.com/in/lihua-yu-5b3337)
Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Yongjiang Hei (黑永疆), Co-CEO @ Biocity Biopharma
( http://linkedin.com/in/yonghei)
Wenjun Wu (Armstrong, 吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Ethan Xu
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
封面图来源：123rf
往期推荐
一周两笔！恒瑞、信达接连出海的“DLL3”什么来头？
重磅！全球首款 CLDN18.2 单抗国内获批上市！
2025年，拥有优质二期临床数据的Biotech更能吸引投资？
版权声明/免责声明
本文为授权转载文章。
本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。
文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。
如有任何问题，请与我们联系。
衷心感谢!
药时代官方网站:www.drugtimes.cn
联系方式:
电话:13651980212
微信:27674131
邮箱:contact@drugtimes.cn
